Copyright
©The Author(s) 2025.
World J Clin Oncol. Jun 24, 2025; 16(6): 106798
Published online Jun 24, 2025. doi: 10.5306/wjco.v16.i6.106798
Published online Jun 24, 2025. doi: 10.5306/wjco.v16.i6.106798
Figure 2 Kaplan-Meier analyses.
A: Overall survival; B: Progression-free survival according to treatment groups after propensity score matching. EH: Emergency hepatectomy; PSM: Propensity score matching; SH: Staged hepatectomy; TACE-L: Transarterial chemoembolization combined with lenvatinib; TACE-L-P: Transarterial arterial chemoembolization combined with lenvatinib plus death protein-1 inhibitors.
- Citation: Liu S, Liu YH, Ni HB, Li JJ, Wu ZT, Wang LL, Ruan Y, Zhou XH. Transarterial chemoembolization plus lenvatinib with or without protein-1 inhibitor for hepatocellular carcinoma with portal vein tumor thrombus. World J Clin Oncol 2025; 16(6): 106798
- URL: https://www.wjgnet.com/2218-4333/full/v16/i6/106798.htm
- DOI: https://dx.doi.org/10.5306/wjco.v16.i6.106798